Posted on Leave a comment

RI Lists Pfizer Booster Availability Tiers

[CREDIT: CDC] An image of the novel coronavirus that causes COVID-19. COVID-19 variant B-117, the most common in the U.S., is also spreading in RI, and is 50% more transmissible and 50% more deadly. Pfizer booster shots against the virus are now available in RI.

[CREDIT: CDC] An image of the novel coronavirus that causes COVID-19. COVID-19 variant B-117, the most common in the U.S., is also spreading in RI, and is 50% more transmissible and 50% more deadly. Pfizer booster shots against the virus are now available in RI.
[CREDIT: CDC] An image of the novel coronavirus that causes COVID-19. COVID-19 variant B-117, the most common in the U.S., is also spreading in RI, and is 50% more transmissible and 50% more deadly. Pfizer booster shots against the virus are now available in RI.
PROVIDENCE — Since the FDA granted a new emergency use authorization for specific populations’ Pfizer vaccine booster shots against COVID-19, RI has set availability in four tiers, starting with people 65 years and older and residents in long-term care settings.

“Rhode Island was well prepared for COVID-19 booster shot administration. I am pleased to see that eligible Rhode Islanders are already stepping up to get their booster shots,” said Governor Dan McKee. “We had the infrastructure and strategy in place to respond swiftly to the approval from CDC, FDA, and ACIP and ensured boosters could be administered as soon as possible. Rhode Island continues to lead the nation in vaccinations and testing and we will continue to lead as we begin administering booster shots.”

The tiers of booster shot availability in the Ocean State, according to the RI Department of Health, are:

  • People 65 years and older and residents in long-term care settings (regardless of age) should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,  
  • People aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
  • People aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks,
  • People aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.

Eligible Rhode Islanders  who number about 130,000, according to a state estimate, can now make appointments for booster doses. We expect small changes in online systems for registration over the coming days to reflect new eligibility and thank Rhode Islanders in advance for their patience. Only the Pfizer booster has received FDA Emergency Use Authorization.

Demand is expected to be higher for the next six weeks than it has been for the past several months, given the state’s very high vaccination rates. For all Rhode Islanders, 74.8% have received at least one dose and 67.4% are fully vaccinated. For those 12 or older, 85.2% have received one dose, while 76.6% are fully vaccinated. People are strongly encouraged to make an appointment to get vaccinated, when possible, to ensure that enough vaccine is available at the site and to reduce wait times. You can make an appointment at C19vaccineRI.org. If you need assistance making an appointment, please call 844-930-1779, 401-222-8022, or 211.

Rob Borkowski
Author: Rob Borkowski

Rob has worked as reporter and editor for several publications, including The Kent County Daily Times and Coventry Courier, before working for Gatehouse in MA then moving home with Patch Media. Now he's publisher and editor of WarwickPost.com. Contact him at [email protected] with tips, press releases, advertising inquiries, and concerns.

This is a test